Mark Sabag, Executive Vice President of International Markets Commercial at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), recently sold a substantial block of the company's ordinary shares. The ...
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Zacks.com on MSN3d
Axsome Stock Surges 20% on Auvelity Patent Settlement With TevaShares of Axsome Therapeutics AXSM jumped 20.2% on Monday after the company announced that it has entered into a settlement ...
Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...
Teva Pharmaceutical ( NYSE: TEVA) shares snapped six straight sessions of losses, as the stock closed 0.88% higher at $17.21 ...
Pyridostigmine bromide extended-release tablets: Alvogen and Rising Pharmaceuticals have both reported shortages of pyridostigmine bromide 180-milligram, extended-release tablets. Rising estimated ...
Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...
Teva Pharmaceutical Industries Limited (NYSE:TEVA – Free Report) by 15.0% during the 4th quarter, according to its most ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback